BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:barzolvolimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of barzolvolimab\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07266402-1321@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:barzolvolimab: Phase 3 readout est. (NCT07266402)
DESCRIPTION:barzolvolimab\, phase 3\, Chronic Inducible Urticaria.\nStudy: 
 A Study to Investigate Efficacy\, Safety and Tolerability of Barzolvolimab
  Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Derm
 ographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and
  SD)\nEstimated primary completion: June 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/barzolvolimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07266402
URL:https://assetmemo.bio/drug/barzolvolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256392-1321@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:barzolvolimab: Phase 3 readout est. (NCT07256392)
DESCRIPTION:barzolvolimab\, phase 3\, Chronic Spontaneous Urticaria.\nStudy
 : Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in 
 Participants With Chronic Spontaneous Urticaria\nEstimated primary complet
 ion: September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 barzolvolimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07256392
URL:https://assetmemo.bio/drug/barzolvolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
